Search
Denufosol
go.drugbank.com/drugs/DB04983InvestigationalDenufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnIt is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … [DB00104] is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as
Insulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalInsulin glargine is also available as the biosimilar, or "follow-on" product, Basaglar in the US and as Abasaglar in the EU. … Due to its duration of action, Lantus is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight.
Mixtures: SOLİQUA SOLOSTAR 100 U/ML + 33 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEM, SOLİQUA SOLOSTAR 100 U/ML + 50 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEMProducts: BASALOG 100 IU/mL, SOLUTION FOR INJECTION IN A VIAL, LANTUS® 100 IU/MLMethylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalMethylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. … It is also a weak CYP2D6 inhibitor. FDA approved in 2008.
Categories: Heterocyclic Compounds with 4 or More RingsEravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalEravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive … of anaerobic pathogens [A38683].
Categories: Monoamine Oxidase A Substrates, combinations of tetracyclinesIoglunide
go.drugbank.com/drugs/DB21276ExperimentalIoglunide is a small molecule drug. Ioglunide has a monoisotopic molecular weight of 806.86 Da.
Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of ChemicalsHaloprogin
go.drugbank.com/drugs/DB00793ApprovedWithdrawnHaloprogin is used as a topical ointment or cream in the treatment of Tinea infections. … Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton).
Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigationalDabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran]. … [A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated.
Albutrepenonacog alfa
go.drugbank.com/drugs/DB13884ApprovedIt is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305] … Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin).
Products: IDELVION 250 IU powder and solvent for solution for injection, IDELVION 500 IU powder and solvent for solution for injectionPegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigational[L42725] It is advantageous over currently available management therapies for PKU, such as [DB00360], that are ineffective to many patients due to long-term adherence issues or inadequate Phe-lowering … Pegvaliase-pqpz, or PEGylated pegvaliase, is used as a novel enzyme substitution therapy and is marketed as Palynziq for subcutaneous injection.